Transient Gene Expression Seeds Plant-Based Bioproduction Systems
Recent advances in plant biotechnology have allowed the use of plants and plant cell cultures for the production of pharmaceutical proteins, known as molecular farming. We are now able to exploit the ability of...
Sartorius Stedim Biotech, Novasep Partner on Membrane Chromatography
Sartorius Stedim Biotech said today it will partner with Novasep to develop novel systems for membrane chromatography and single-use bioprocessing, through a collaboration whose value was not disclosed.
The collaboration is intended to develop innovative...
Cell-Free Protein Synthesis Made Flexible and Accessible
Researchers say they greatly simplified the method for cell-free protein synthesis
Danaher to Acquire GE Life Sciences’ Biopharma Business for $21.4B
Danaher agreed to buy GE Life Sciences biopharma business for approximately $21.4 billion cash, in a deal designed to enhance the buyer’s bioprocessing offerings and pay down the seller’s debt. Following completion of the acquisition, GE Biopharma will operate as a standalone company within Danaher’s Life Sciences segment
Key Cell Culture Technology Trends
GEN‘s contributing editor K. John Morrow, Jr., PhD, recently interviewed several cell culture technology experts to gain some insights on choosing the right cell line, improving production rates, and addressing the challenge of protein modification in CHO cells.
Sanofi Inks Bispecific Antibody Deal with Biomunex
Sanofi will use Biomunex Pharmaceuticals’ proprietary BiXAb® platform for generating and optimizing bi- and multi-specific antibodies to develop new treatments in immuno-oncology and other therapeutic areas.
The companies have signed a licensing agreement whose value...
Fujifilm to Build New U.K. Center of Excellence
Fujifilm Diosynth Biotechnologies’ Center of Excellence will be built in partnership with the University of Edinburgh, University of Manchester, and University of York.
SGS Expands Glasgow Facility’s Testing Capabilities
As the pharmaceutical industry becomes increasingly focused on large molecule biologics, vaccines, gene and cell therapies, SGS says it will continue to increase its service capacity and capabilities in these areas.
Filtration Focuses on Capacity and Concentration Pain Points
A therapeutic protein or monoclonal antibody (mAb) can be turned into an effective therapy and a revenue-generating product only if it can be efficiently filtered from the process stream. If a product is inefficiently...
Transferring Viral Vector Production from Plasticware to a Fixed-Bed Bioreactor
Gene and modified cell therapies (for example, chimeric antigen receptor T-cell therapies) in early to late clinical development are showing significant promise to treat and potentially cure many diseases. A few of these...
